SANTIAGO DE CUBA, Cuba, Oct 2 (ACN) Cuba’s Finlay Vaccine Institute (IFV) and the General Division of Health in the province of Santiago de Cuba signed a cooperation agreement to evaluate the immunogenicity, safety and effectiveness of an 11-valent pneumococcal conjugate vaccine candidate for children developed in the country.
Meiby Rodríguez, IFV’s director of Clinical Research and Impact Assessment, highlighted the importance of having this new product registered and included in the National Immunization Program and made reference to further studies on invasive and non-invasive pneumococcal disease in children below